SECURITIES AND EXCHANGE COMMISSION
 
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
 
Date of Report (Date of earliest event reported):  May 16, 2017 (May 11, 2017)


CHEMBIO DIAGNOSTICS, INC.
(Exact name of registrant as specified in its charter)
 
Nevada
 
0-30379
 
88-0425691
(State or other jurisdiction
 
(Commission File Number)
 
(IRS Employer
of Incorporation)
     
Identification Number)
   
3661 Horseblock Road
   
   
Medford, NY 11763
   
   
(Address of principal executive offices)
   
   
631-924-1135
   
   
(Registrant's Telephone Number)
   
 
N/A
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Item 5.07 SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

At the Company's annual stockholder meeting on May 11, 2017, stockholders elected the directors of the Company named below to serve until the next annual meeting of stockholders or until their respective successors are elected and qualified.  Stockholders also ratified the selection of BDO USA LLP as the Company's independent registered certified accountants to audit the Company's financial statements as of and for the year ending December 31, 2017, and approved, on an advisory basis, the compensation paid to the Company's named executive officers.  A tabulation of the matters voted on at this annual stockholder meeting is set forth below.

Proposal #1:– Election of Directors
 
Kathy L. Davis
 
Peter Kissinger
 
Dr. Gary Meller
 
John J. Sperzel III
For
 
 5,356,287
 
5,356,338
 
5,354,456
 
5,779.281
Withheld/Against
 
    574,328
 
 574,277
 
 576,159
 
  151,334
Broker non-votes
 
 4,617,503
 
4,617,503
 
4,617,503
 
4,617,503

 

 
 
 
      Proposal #2     Proposal #3
 
 
Ratifying BDO USA LLP as the Company's Independent Auditors for the year ending December 31, 2017
 
Approve Compensation paid to the Company's named Executive Officers
For
 
10,524,627
 
5,669,227
Withheld/Against
 
13,548
 
152,402
Abstain
 
9,943
 
108,986
Broker non-votes
 
---
 
4,617,503



Proposals #4 and #5 :

There were no votes undertaken concerning Other Business or to Adjourn or Postpone the Meeting.



 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


Date:  May 16, 2017                               Chembio Diagnostics, Inc.



By:    /s/ Richard J. Larkin                                       
Richard J. Larkin
Chief Financial Officer


Chembio Diagnostics (NASDAQ:CEMI)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Chembio Diagnostics Charts.
Chembio Diagnostics (NASDAQ:CEMI)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Chembio Diagnostics Charts.